Background The progression of prostate cancer to castration-resistant prostate cancer
(CRPC) is often a result of somatic alterations in the PI3K/Akt/mTOR (mammalian target of …

Background Prostate cancer is one of leading causes of cancer death among men
worldwide. Androgen deprivation therapy is a central part of the prostate cancer treatment …

BACKGROUND The mammalian target of rapamycin (mTOR) pathway is up‐regulated in
castration‐resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …

Background: The mammalian target of rapamycin (mTOR) pathway is deregulated in
castration-resistant prostate cancer (CRPC). We investigated the efficacy and toxicity of …

The phosphatidylinositol 3'-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR)
signaling pathway contributes to prostate cancer progression and transition to androgen …

Abstract Lessons Learned The combination of standard dose abiraterone acetate and
BEZ235, a pan‐class I PI3K and mTORC1/2 inhibitor, was poorly tolerated in men with …

Background Few options are available after taxane-based therapy in men with CRPC.
Genetic alterations involving the mTOR pathway have been associated with CRPC …

Background MLN0128 is a first-in-class, dual mTOR inhibitor with potential to outperform
standard rapalogs through inhibition of TORC1 and TORC2. This phase II study was …

Background Activation of the PI3K-Akt-mTOR signaling pathway is common in advanced
castration resistant prostate cancer (CRPC), typically through PTEN loss. Preclinical studies …

Background CC-115, a dual mTORC1/2 and DNA-PK inhibitor, has promising antitumour
activity when combined with androgen receptor (AR) inhibition in pre-clinical models …